AstraZeneca and Bristol Myers Squibb are reportedly circling a merger that could create a pharmaceutical giant worth more than £300 billion. If it ever gets past the talking stage, the combination would rank among the industry's biggest deals and could create the world's fourth-largest drugmaker.
The Financial Times first reported the discussions, according to The Independent. The talks have taken place in recent months, but no agreement is in hand, and sources cautioned that the proposal could be delayed or fall apart.
Why The Two Drugmakers Could Fit
AstraZeneca is based in Cambridge, England, but its U.S. ambitions are increasingly visible. The company's latest SEC filing says AstraZeneca's ordinary shares began trading directly on the New York Stock Exchange on February 2, after the company ended its American depositary receipt program.
Bristol Myers Squibb brings a major oncology business alongside a deep cardiovascular portfolio, according to the company's research pages on cancer medicines and heart disease treatments. Its first-quarter 2026 results showed $11.5 billion in revenue, while the company reaffirmed full-year revenue guidance of roughly $46 billion to $47.5 billion in a regulatory filing.
The strategic appeal is fairly obvious: AstraZeneca would gain even more scale in the United States, while BMS would join forces with a global rival whose pipeline is also heavily weighted toward oncology. That overlap is the deal's selling point and its biggest headache, because combining two large cancer franchises could create a formidable competitor while inviting questions about duplicated treatments and research programs.
Regulators Would Have A Long Checklist
Any transaction of this size would face scrutiny from U.S. antitrust authorities. The Federal Trade Commission says large mergers generally must be reported under the Hart-Scott-Rodino Act, and regulators can demand additional information or sue to block a deal they believe would substantially reduce competition.
The Justice Department's merger guidelines specifically warn that a transaction can raise concerns when it eliminates substantial competition between the companies, including competition involving future products and research. In Britain, the Competition and Markets Authority can also examine whether a deal has a realistic prospect of substantially lessening competition, with an initial review that can lead to a deeper phase-two investigation.
America Is Already Part Of AstraZeneca's Strategy
The reported merger talks arrive as AstraZeneca is expanding its American footprint. In a company announcement, AstraZeneca said it planned to invest $3.5 billion in U.S. research and manufacturing by the end of 2026, including projects in Massachusetts, Maryland, Texas and cell-therapy facilities on both coasts.
That investment makes a U.S.-based combination look strategically consistent with AstraZeneca's recent direction, even if it would represent a dramatic escalation. For now, though, this remains a reported conversation rather than a signed transaction.
AstraZeneca declined to comment, while Bristol Myers Squibb was contacted for a response, The Independent reported. Until the companies disclose more, the proposed pharma colossus exists only on paper—and regulators would have plenty to say before that paper could become a deal.
